Lower plasma Coenzyme Q10 in depression: A marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness

Neuroendocrinology Letters

Volumn 30, Issue 4, 2009, Pages 462-469

  Maes, Michael ^a   Mihaylova, Ivanka ^a   Kubera, Marta ^b   Uytterhoeven, Marc ^c   Vrydags, Nicolas ^c   Bosmans, Eugene ^c  

^a Maes Clinics   (Belgium)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c AML Laboratory   (Belgium)

Author keywords

Cardiovascular disorder; Chronic fatigue syndrome; Coenzyme Q10; Cytokines; Inflammation; Major depression; Mitochondria; Oxidative stress; Statins

Indexed keywords

UBIDECARENONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HAMILTON SCALE; HUMAN; MALE; SUPPLEMENTATION;

EID: 76049090965     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Abd El-Gawad HM, Khalifa AE (2001). Quercetin, coenzyme Q10, and L-canavanine as protective agents against lipid peroxidation and nitric oxide generation in endotoxin-induced shock in rat brain. Pharmacol Res. 43(3): 257-263.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Text Revision (DSM-IV-TR). Washington DC.
3. Anisman H, Merali Z, Poulter MO, Hayley S (2005). Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Design. 11(8): 963-972.
4. Belardinelli R, Muçaj A, Lacalaprice F, Solenghi M, Principi F, Tiano L, Littarru GP (2005). Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors. 25(1-4): 137-145.
5. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, Gouni-Berthold I (2006). Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 29(8): 703-712.
6. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M (2002). Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 22(1): 86-90.
7. Bonakdar RA, Guarnerl E (2005). Coenzyme Q10. Am Fam Physician. 72(6): 1065-1070.
8. Butler MG, Dasouki M, Bittel D, Hunter S, Naini A, DiMauro S (2003). Coenzyme Q10 levels in Prader-Willi syndrome: comparison with obese and non-obese subjects. Am J Med Genet A. 119A(2): 168-171.
9. Campbell S, MacQueen G (2006). An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry. 19(1): 25-33.
10. Caso G, Kelly P, McNurlan MA, Lawson WE (2007). Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 99(10): 1409-1412.
11. Chapidze G, Kapanadze S, Dolidze N, Bachutashvili Z, Latsabidze N (2005). Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant coenzyme Q10 and statins. Georgian Med News. 118: 20-25.
12. Chaturvedi RK, Beal MF (2008). Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 1147: 395-412.
13. Chu CS, Kou HS, Lee G, Lee KT, Chen SH, Voon WC, Sheu SH, Lai WT (2006). Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia. Biofactors. 28(3-4): 177-184.
14. Crane FL (2001). Biochemical functions of coenzyme Q10. J Am Coll Nutr. 20(6): 591-598.
15. Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH (2008). Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 15(12): 1371-1379.
16. Dickens C, McGowan L, Percival C, Tomenson B, Cotter L, Heagerty A, Creed F (2008). New onset depression following myocardial infarction predicts cardiac mortality. Psychosom Med. 70(4): 450-455.
17. Dutton PL, Ohnishi T, Darrouzet E, Leonard, MA, Sharp RE, Cibney BR, Daldal F and Moser CC (2000). Coenzyme Q oxidation reduction reactions in mitochondrial electron transport (pp 65-82). In: Kagan VE and Quinn PJ, editors. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press. pp. 65-82.
18. Forlenza MJ, Miller GE (2006). Increased serum levels of 8-hydroxy-2′-deoxyguanosine in clinical depression. Psychosomatic Med. 68(1): 1-7.
19. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994). The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 121(12): 953-959.
20. Gardner A, Johansson A, Wibom R, Nennesmo I, von Döbeln U, Hagenfeldt L, Hällström T (2003). Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord. 76(1-3): 55-68.
21. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, Yirmiya R (2008). Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry. 13(7): 717-728.
22. Gutteridge JMC, Halliwell B (1994). Antioxidants in Nutrition, Health and Disease. Oxford: Oxford University Press.
23. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry. 23: 56-61.
24. Huang KL, Su TP, Chen TJ, Chou YH, Bai YM (2009). Comorbidity of cardiovascular diseases with mood and anxiety disorder: a population based 4-year study. Psychiatry Clin Neurosci. 63(3): 401-409.
25. Ishrat T, Khan MB, Hoda MN, Yousuf S, Ahmad M, Ansari MA, Ahmad AS, Islam F (2006). Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behav Brain Res. 171(1): 9-16.
26. Jakobsen AH, Foldager L, Parker G, Munk-Jorgensen P (2008). Quantifying links between acute myocardial infarction and depression, anxiety and schizophrenia using case register databases. J Affect Disord. 109(1-2): 177-181.
27. Keith M, Mazer CD, Mikhail P, Jeejeebhoy F, Briet F, Errett L (2008). Coenzyme Q10 in patients undergoing CABG: Effect of statins and nutritional supplementation. Nutr Metab Cardiovasc Dis. 18(2): 105-111.
28. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R (2003). Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 8(6): 365-370.
29. Koo JW, Duman RS (2008). IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Nat Acad Sci USA. 105: 751-756.
30. Kooncumchoo P, Sharma S, Porter J, Govitrapong P, Ebadi M (2006). Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci. 28(2): 125-141.
31. Kubera M, Van Bockstaele D, Maes M (1999). Leukocyte subsets in treatment-resistant major depression. Pol J Pharmacol. 51(6): 547-549.
32. Kucharská J, Gvozdjáková A, Simko F (2007). Simvastatin decreased coenzyme Q in the left ventricle and skeletal muscle but not in the brain and liver in L-NAME-induced hypertension. Physiol Res. 56 Suppl 2: S49-54.
33. Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA (2005). Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors. 25(1-4): 147-152.
34. Li FC, Tseng HP, Chang AY (2005). Neuroprotective role of coenzyme Q10 against dysfunction of mitochondrial respiratory chain at rostral ventrolateral medulla during fatal mevinphos intoxication in the rat. Ann N Y Acad Sci. 1042: 195-202.
35. Li G, Zou LY, Cao CM, Yang ES (2005). Coenzyme Q10 protects SHSY5Y neuronal cells from beta amyloid toxicity and oxygen-glucose deprivation by inhibiting the opening of the mitochondrial permeability transition pore. Biofactors. 25(1-4): 97-107.
36. Littarru GP, Langsjoen P (2007). Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 7 Suppl: S168-174.
37. Littarru GP, Tiano L (2007). Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 37(1): 31-37.
38. Liu J (2008). The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res. 33(1): 194-203.
39. Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J, Kobayashi J (2005). Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb. 12(2): 111-119.
40. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, Koizumi J; Hokuriku Lipid Research Group (2007). Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. 195(2): e182-189.
41. Maes M (1993). A review on the acute phase response in major depression. Rev Neurosci. 4(4): 407-416.
42. Maes M (1995). Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 19(1): 11-38.
43. Maes M (1999). Major depression and activation of the inflammatory response system. Adv Exp Med Biol. 461: 25-46.
44. Maes M (2008). The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett. 29(3): 287-291.
45. Maes M, Meltzer HYM (1995). The serotonin hypothesis of major depression. In: F.Bloom and D.Kupfer, editors. Psychopharmacology, the Fourth Generation of Progress. New York: Raven Press. pp. 933-941.
46. Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J (1990-1991). Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology. 24(3): 115-120.
47. Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J (1991). Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand. 84(4): 379-386.
48. Maes M, Meltzer HY, Cosyns P, Schotte C (1994). Evidence for the existence of major depression with and without anxiety features. Psychopathol. 27: 1-13.
49. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997a). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9(11): 853-858.
50. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyder R (1997b). Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry. 42(5): 349-358.
51. Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A (2000). Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord. 58(3): 241-246.
52. Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Meltzer H (2001). Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry. 6(4): 475-480.
53. Maes M, Mihaylova I, Bosmans E (2007a). Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett. 28(4): 456-462.
54. Maes M, Mihaylova I, Kubera M, Bosmans E (2007b). Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett. 28(4): 463-469.
55. Maes M, Mihaylova I, Leunis JC (2007c). Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. Neuro Endocrinol Lett. 28(6): 861-867.
56. Maes M, Mihaylova I, Ategis J-C (2008). Evidence for an IgM-mediated immune response directed against nitro-bovine serum albumin (BSA) in chronic fatigue syndrome (CFS) and major depression (MDD): evidence that the immune response to nitrosative stress-induced damage of BSA is more pronounced in CFS than in MDD. Neuro Endocrinol. Lett. 29: 313-319.
57. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2009a). Coenzyme Q10 deficiency in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett. 30: 470-476.
58. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009b). The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 24(1): 27-53.
59. Matthews RT, Yang L, Browne S, Baik M, Beal MF (1998). Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. 95(15): 8892-8897.
60. Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM (2008). Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 52(18): 1435-1441.
61. O'Brien, SM, Scully P, Fitzgerald P, Scott LV, Dinan TG (2007). Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. 41(3-4): 326-331.
62. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O (2004). Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 19(2): 89-95.
63. Pal SN, Dandiya PC (1994). Glutathione as a cerebral substrate in depressive behavior. Pharmacol Biochem Behav. 48(4): 845-851.
64. Palan PR, Mikhail MS, Shaban DW, Romney SL (2003). Plasma concentrations of coenzyme Q10 and tocopherols in cervical intra-epithelial neoplasia and cervical cancer. Eur J Cancer Prev. 12(4): 321-326.
65. Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP (2003). Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors. 18(1-4): 113-124.
66. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT (2007). Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 55(5): 453-462.
67. Rezin GT, Cardoso MR, Gonçalves CL, Scaini G, Fraga DB, Riegel RE, Comim CM, Quevedo J, Streck EL (2008). Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem Int. 53(6-8): 395-400.
68. Rusciani L, Proietti I, Rusciani A, Paradisi A, Sbordoni G, Alfano C, Panunzi S, De Gaetano A, Lippa S (2006). Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol. 54(2): 234-241.
69. Sander S, Coleman CI, Patel AA, Kluger J, White CM (2006). The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 12(6): 464-472.
70. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S (2007). Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol. 22(2): 67-73.
71. Schiepers OJ, Wichers MC, Maes M (2005). Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 29(2): 201-217.
72. Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F (2008). Functions of coenzyme Q10 in inflammation and gene expression. Biofactors. 32(1-4): 179-183.
73. Schmelzer C, Lorenz G, Rimbach G, Döring F (2007a). Influence of Coenzyme Q-{10} on release of pro-inflammatory chemokines in the human monocytic cell line THP-1. Biofactors. 31(3-4): 211-217.
74. Schmelzer C, Lorenz G, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F (2007b). Effects of Coenzyme Q10 on TNF-alpha secretion in human and murine monocytic cell lines. Biofactors. 31(1): 35-41.
75. Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Bunney WE, Vawter MP (2008). Mitochondrial involvement in psychiatric disorders. Ann Med. 40(4): 281-295.
76. Shively CA, Musselman DL, Willard SL (2009). Stress, depression, and coronary artery disease: modeling comorbidity in female primates. Neurosci Biobehav Rev. 33(2): 133-144.
77. Siciliano G, Mancuso M, Tedeschi D, Manca ML, Renna MR, Lombardi V, Rocchi A, Martelli F, Murri L (2001). Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain Res Bull. 56(3-4): 405-410.
78. Singh RB, Neki NS, Kartikey K, Pella D, Kumar A, Niaz MA, Thakur AS (2003). Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. 246(1-2): 75-82.
79. Singh U, Devaraj S, Jialal I (2007). Coenzyme Q10 supplementation and heart failure. Nutr Rev. 65(6 Pt 1): 286-293.
80. Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S (2005). Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol Dis. 18(3): 618-627.
81. Somberg TC, Arora RR (2008). Depression and heart disease: therapeutic implications. Cardiology. 111(2): 75-81.
82. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HB, Friedman L and Rajkowska G (2004). Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry. 56(9): 640-650.
83. Sugino K, Dohi K, Yamada K, Kawasaki T (1987). The role of lipid peroxidation in endotoxin-induced hepatic damage and the protective effect of antioxidants. Surgery. 101(6): 746-752.
84. Suomalainen A, Majander A, Haltia M, Somer H, Lönnqvist J, Savontaus ML, Peltonen L (1992). Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. J Clin Invest. 90(1): 61-66.
85. Tavintharan S, Ong CN, Jeyaseelan K, Sivakumar M, Lim SC, Sum CF (2007). Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol. 223(2): 173-179.
86. Thase ME, Rush AJ (1995). Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the Fourth Generation of Progress. New York: Raven Press. pp 1081-1098.
87. Tiano L, Belardinelli R, Carnevali P, Principi F, Seddaiu G, Littarru GP (2007). Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J. 28(18): 2249-2255.
88. Van Hunsel F, Wauters A, Vandoolaeghe E, Neels H, Demedts P, Maes M (1996). Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments. Psychiatr Res. 20: 159-169.
89. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M (2005). IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 10(6): 538-344.
90. Yalcin A, Kilinc E, Sagcan A, Kultursay H (2004). Coenzyme Q10 concentrations in coronary artery disease. Clin Biochem. 37(8): 706-709.
91. Young AJ, Johnson S, Steffens DC, Doraiswamy PM (2007). Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 12(1): 62-68.
92. Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG (2002). A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res. 52(6): 501-509.
93. Zweig MH, Campbell G (1993). Receiver operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 39: 561-577.